X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Efficacy Shown On Cystic Fibrosis Patients In 4-Year Study

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Efficacy Shown On Cystic Fibrosis Patients In 4-Year Study

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home News

CMS Tests Three New Ways To Bring Down The Cost of Drugs

Content Team by Content Team
17th February 2023
in News

It has come to light that the federal health agencies have gone on to select three new models so as to lower the prices of the drugs and work on President Joe Biden’s executive order that targets the drug costs. These models are going to be tested through the CMS Innovation Center.

The president has directed his administration to lower drug prices in Executive Order No. 14087, which is referred to as Lowering Prescription Drug Costs for Americans. Tagged with the Inflation Reduction Act of 2022, CMS can go on to have substantial power to negotiate as well as lower the prices of drugs for many Americans. The IRA has given the CMS the ability to negotiate prices for Medicare for the very first time in history. The Department of Health and Human Services has released the timeline so as to implement the first round of drugs that will be targeted.

According to Xavier Becerra, the HHS Secretary, HHS is going to be using every tool that is available to lessen the healthcare cost and at the same time, elevate the access to high quality as well affordable healthcare. They are going all out to deliver the cost savings from the president’s rolled-out Inflation Reduction Act of 2022. Apparently, as per him, people on Medicare are already feeling the benefits. President Biden has however also made it clear that there has to be further action involved when it comes to building on the new prescription drug law and that is why HHS is executing these new projects so as to bring the drug cost down.  

The models selected by Becerra meet the standards when it comes to affordability, feasibility, and accessibility in terms of implementation. These models have in them the Medicare $2 Drug List, cell and gene therapy access, and an accelerating clinical evidence model. The Medicare $2 Drug List model takes care of chronic conditions like high blood pressure as well as high cholesterol. Many patients who happen to be facing such conditions experience a cost-sharing gap when it comes to generic medications, which can have significant benefits. The model will encourage Medicare Part D drug plans to give low and fixed co-payments across all the cost-sharing phases of the Part D drug benefit for generic drugs on a standardised list that treat chronic conditions.

The Cell and Gene Therapy Access model looks to lessen the huge costs involved in cell and gene therapies, which happen to be emerging areas of medicine that can cost more than $1 million. This model has state Medicaid agencies assign the CMS to partner with and administer multi-state agreements with manufacturers for certain set of cell and gene therapies. This goes on to help Medicaid beneficiaries have access to these life-saving treatments as well as high-cost specialty drugs.

Accelerating clinical evidence model enables the CMS to bring out payment methods for drugs that are approved under the accelerated approval and in-consultation with the FDA so as to encourage timely trial completion and enhance the access to the post-market safety as well as efficacy data.

These selected models are going to test the strategies to help make it easier for Medicare enrolees to afford as well as access the required prescriptions for $2 or even less and thereby help broaden the cutting-edge cell and gene therapy for people having Medicaid. They look forward to working on these listed models and help making the drug cost lower with the help of Medicaid and Medicare, says Liz Fowler, Deputy Administrator and Director of the CMS Innovation Center.

Previous Post

Clinical Trials Diversity - A Much To Be Explored Segment

Next Post

Neoadjuvant Nivolumab Aids In Long Term Lung Cancer Survival

Related Posts

Drug Development

Nasal Spray Shows Its Effect Against New COVID Variants

27th March 2023
FDA Approvals

Mid-Point Regulatory Science Strategy Study Published By EMA

27th March 2023
Drug Development

AADC Inadequacy To Be Handled By A Novel Gene Therapy

24th March 2023
Drug Development

New Drug Explored For Epilepsy Gets $3M Funding In Australia

23rd March 2023
Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials
Clinical Trials

Faster Clinical Trial Nods Planned By The UK To Curb Issues

22nd March 2023
Pharma Drugs Gain From Tardigrade Proteins, Says Research
Drug Development

Pharma Drugs Gain From Tardigrade Proteins, Says Research

22nd March 2023
Next Post

Neoadjuvant Nivolumab Aids In Long Term Lung Cancer Survival

Latest News

Drug Development

Nasal Spray Shows Its Effect Against New COVID Variants

27th March 2023
FDA Approvals

Mid-Point Regulatory Science Strategy Study Published By EMA

27th March 2023
Drug Development

AADC Inadequacy To Be Handled By A Novel Gene Therapy

24th March 2023
Drug Development

New Drug Explored For Epilepsy Gets $3M Funding In Australia

23rd March 2023
Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials
Clinical Trials

Faster Clinical Trial Nods Planned By The UK To Curb Issues

22nd March 2023
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In